Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: trastuzumab|DRUG: tipifarnib
Sponsor: The University of Texas Health Science Center at San Antonio
Collaborators: National Cancer Institute (NCI)